Merck Discontinues Bacterial Infection Drug Zinplava
The European Commission has withdrawn the marketing authorization for the antibiotic treatment at the request of the manufacturer.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when choosing to discontinue existing medications?
Merck & Co. is permanently discontinuing its bacterial infection drug, Zinplava, for commercial reasons. The European Commission formally withdrew the medication's marketing authorization on October 20, 2026.
Why it matters
The move follows Merck's earlier decision to discontinue the drug in the United States in December 2024. The withdrawal marks the end of the therapy's availability in both major markets.
Merck & Co. saw its stock price reach $148.21, reflecting a 3.19% increase. The discontinued treatment had previously been approved for pediatric patients as young as one year of age.
The players
Merck & Co.
Merck & Co. is a multinational pharmaceutical company that develops and manufactures a wide range of medicines and vaccines.
European Commission
The European Commission is the executive branch of the European Union responsible for proposing legislation and implementing decisions.
The details
Merck Sharp & Dohme B.V. submitted a direct notification to European regulators requesting the withdrawal of the drug's marketing authorization. This action terminates the life cycle of the product, which had previously secured unlimited validity status in 2021.
Timeline
January 18, 2017: European regulators granted Zinplava initial five-year marketing authorization.
2021: The European Commission granted the treatment unlimited validity.
December 2023: The drug indication was extended to include pediatric patients.
December 2024: Merck discontinued the therapy in the United States.
October 20, 2026: The European Commission formally withdrew marketing authorization.
Market Landscape
The withdrawal of Zinplava aligns with broader industry trends where pharmaceutical firms optimize portfolios by discontinuing older treatments to focus on high-growth assets. This move reduces the product offerings under Merck & Co. following similar strategic exits in other regions.
Patients and healthcare providers in the European Union will no longer have access to Zinplava as a treatment option for bacterial infections. Medical professionals should consult alternative therapies for patients previously considered for this medication.
The takeaway
The decision to pull Zinplava underscores the importance of commercial viability in the long-term support of medical treatments. Clinicians and patients should remain aware of medication availability and discuss updated treatment protocols with their providers.
Further reading
For more on industry developments, visit the Healthcare section.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access when choosing to discontinue existing medications?
